BGC 20-1531 hydrochloride
Cat. No. 5327
Alternative Name: PGN 1531
Chemical Name: 4-[[4-(5-Methoxy-2-pyridinyl)phenox
Biological ActivityHigh affinity and selective EP4 antagonist (Ki = 3 nM). Exhibits >2500-fold selectivity for EP4 over EP2 and EP3. Also selective over a range of other prostanoid receptors, ion channels, transporters and enzymes. Inhibits PGE2-induced vasodilation of middle cerebral and meningeal arteries in vitro, and carotid blood flow in vivo. Orally bioavailable.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
Sutton et al (2014) From virtual to clinical: The discovery of PGN-1531, a novel antagonist of the prostanoid EP4 receptor. Bioorg.Med.Chem.Lett. 24 2212. PMID: 24703233.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses BGC 20-1531 hydrochloride from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: BGC 20-1531 hydrochloride, supplier, BGC20-1531, hydrochloride, PGN1531, high, affinity, selective, EP4, antagonists, orally, bioavailable, active, Tocris Bioscience, Prostanoid Receptor Antagonist products
Find multiple products by catalog number
New Products in this Area
Highly potent P2Y12 antagonistFTY 720
Potent S1P receptor agonist; also immunosuppresentCinacalcet hydrochloride
Calcium-sensing receptor (CaSR) allosteric agonist; also CYP2D2 inhibitor and Ca2+ channel blocker; orally bioavailableAMG 837 hemicalcium salt
Potent free fatty acid receptor 1 (FFA1/GPR40) partial agonistUMB 68
GHB receptor ligandAZD 1283
High affinity P2Y12 antagonistEx 26
Potent and selective S1P1 receptor antagonistZQ 16
Selective GPR84 agonistIHR-Cy3
Potent fluorescent Smo antagonistRo 6842262
Potent LPA1 antagonistAMG 853
Potent dual CRTH2 and prostaglandin D2 (PGD2) receptor antagonistAM 4668
Potent FFA1 (GPR40) agonist
April 22 - 26, 2017
Chicago, IL, USA